Onxeo S.A. buy metanicnor
Summary
This prediction ended on 14.03.16 with a price of €3.27. The price of Onxeo S.A. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.03%. metanicnor has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Onxeo S.A. | -4.140% | -4.140% | -69.878% | -85.777% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
Comments by metanicnor for this prediction
In the thread Onxeo S.A. diskutieren
onxeo
la biotech la plus avancée en france mais seulement 152,47 M€ de capitalisation : onxeo vend 3 médicaments : Beleodaq, Sitavig, & Loramyc
à fin juin 2015, la trésorerie se monte à 42.9 M€ donc la prochaine levée de fonds devrait être en 2017
au 1er semestre 2016 la phase III de Validive devrait être lancée
les 1ers résultats de la phase III de Livatag devraient tomber début 2017 : la société annonce un prochain DSMB pour octobre prochain
edison vise 8,1 €
Invest Securities vise 8,7 € depuis le 17/09/2014 après la réunion SFAF de la veille
investir vise 11€ depuis le 4/08/2014
oddo vise 9,6 € depuis 18/12/2014